Back to results
US 6,645,467 B2Granted
Composition and method for decreasing upper respiratory airway resistance
AssigneeScientific Development and Research, Inc.
InventorAlan J. Mautone
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeScientific Development and Research, Inc.
InventorAlan J. Mautone
Estimating the term…
A composition, process and method is disclosed of decreasing mammalian upper respiratory system airway resistance by administering an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form, and one or more propellants, in which the lipid surfactants and spreading agents are not soluble, through a mammalian external airway orifice. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited upon the air/liquid interface resident upon the epithelial lining of the upper respiratory system forming an amorphous spread film thereupon substantially decreasing the resistance to air flow through said upper respiratory system. In a second preferred embodiment, a therapeutically active agent effective in the treatment of upper respiratory disease is added to the mixture of lipid crystals and upon administration of said aerosol mixture, the amorphous spread film formed thereby carries said therapeutically active agent throughout the tissues of the upper respiratory system. In an alternate preferred embodiment, the afore-mentioned reduction of surface tension and delivery of therapeutically active agents is provided by a mixture of lipid crystals comprised of surfactant(s), therapeutically active agents and a propellant in which such other components are not soluble.
A method of reducing resistance to air flow through upper respiratory system airways of a mammal comprising administering a dose of a mixture of lipid crystals, as an aerosol, through an external airway of a mammal, said mixture being comprised of at least one lipid surfactant in an amount effective in lowering surface tension of an air/liquid interface resident upon epithelial tissue lining said upper respiratory system, at least one or more spreading agents in an amount effective in distributing said surfactant within said interface and at least one propellant in which said surfactants and spreading agents are not soluble, said surfactants and said spreading agents being selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, all in powder form;
A method of administering therapeutic agents, effective in the treatment of upper respiratory system pathology, directly to epithelial tissue lining said system while simultaneously decreasing resistance to airflow therethrough comprising administering a dose of a mixture of lipid crystals in combination with said therapeutic agents, as an aerosol, through an external airway of a mammal, said mixture being comprised of at least one lipid surfactants in an amount effective in lowering surface tension of an air/liquid interface resident upon epithelial tissue lining said upper respiratory system and at least one spreading agents in an amount effective in distributing said surfactants upon said interface, at least one therapeutically active agent effective in the treatment of upper respiratory pathology and at least one propellants, said surfactants and said spreading agents being selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, said surfactants, spreading agents and therapeutically active agents all being in powder form and insoluble in the propellants,
A process for preparing an upper respiratory airway enhancing medicament comprising:
A process for preparing an upper respiratory system medicament comprising:
A method of administering therapeutic agents, effective in the treatment of upper respiratory system pathology, directly thereto while simultaneously decreasing airflow resistance therethrough comprising administering a dose of a mixture of lipid crystals in combination with said therapeutic agents, as an aerosolized mixture of lipid crystals, through an external airway of a mammal, said mixture being comprised of at least one lipid surfactant in an amount effective in lowering surface tension of an air/liquid interface resident upon epithelial tissue lining said upper respiratory system, at least one therapeutically active agent effective in the treatment of upper respiratory system pathology and at least one propellant, said lipid surfactants being selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, said surfactants and therapeutically active agents all being in powder form and insoluble in the propellants,
A process for preparing an upper respiratory system medicament comprising:
Dependencies are inferred from the claim text.